J&J/Centocor Files Golimumab In Three Indications
This article was originally published in The Pink Sheet Daily
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
You may also be interested in...
Three Phase III trials prove TNF blocker works in RA – even after others in the class failed.
Agency is investigating approximately 30 reports of cancer in pediatric patients.
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.